{'fraction_non_alphanumeric': 0.023835319609967497, 'fraction_numerical': 0.015167930660888408, 'mean_word_length': 5.947368421052632, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
New targets and new drugs down under in 2004.

The Second Australian Health and Medical Research Congress, held November 21-26, 2004, in Sydney, Australia, brought together 28 specialist societies across a broad range of scientific endeavor. The topics of the plenary lectures included signal transduction by stress-activated mitogen-activated protein kinases, whether human cancer can be treated before it is symptomatic, the modeling of human cardio-myopathies via genetic manipulation in animal models, and biological individuality and the response to regular exercise. The symposia included translating basic research to clinical practice, molecular mechanisms and anticancer therapies, modulating signaling pathways to treat/prevent disease, therapeutic frontiers in bone and joint disease, pleiotropic effects of statins in the cardiovascular system, and angiogenesis inhibitors in cancer and atherosclerosis therapy.